Additional file 1 of Anti-diarrheal drug loperamide induces dysbiosis in zebrafish microbiota via bacterial inhibition

Additional file 1: Supplementary figures: Fig. S1. Sequencing depth and coverage for 16S rRNA gene amplicon data from conventional zebrafish larvae. (A) Number of quality-controlled bacterial sequences per sample. (B). ASV rarefaction curves of all zebrafish larvae samples separated by timepoint and colored by treatment group (n = 5 fish per condition). Fig. S2. Controls for 16S rRNA amplicon sequencing data: blanks and mock community. (A) Expected mock community composition based on 16S rRNA gene copy number and relative percent abundance of each strain. (B) Relative percent abundance of ASVs for each negative or positive sequencing control sample: Zymo mock community standard D6305 (Mock_1 and Mock_2). (C) Relative percent abundance of ASVs for each negative sequencing control sample: negative DNA extraction (Neg_kit1 and Neg_kit2) and negative PCR amplification (Neg_PCR1). The top 10 most abundant ASVs are shown, with all others grouped in the grey “Others” category. Fig. S3. 16S rRNA gene amplicon relative abundances at the phylum level. (A) Bar plot of percent phylum abundance per sample. The top 8 most abundant phyla are shown with the others grouped into “Others” (n = 5 fish per condition). Fig. S4. 16S rRNA gene amplicon relative abundances at the genus level. (A) Bar plot of percent genus abundance per sample. The top 12 most abundant genera are shown with the others grouped into “Others” (n = 5 fish per condition). (B) Number of bacterial genera shared between DMSO and Loperamide-treated samples at each timepoint (vertical bars). The total number of genera detected in each group is shown in the horizontal bar plot on the right. Fig. S5. Beta-diversity metrics of 16S rRNA gene amplicons sequenced from conventional zebrafish. (A) NMDS plot calculated using Bray-Curtis beta-diversity (k=2) of percent normalized ASVs from 16S rRNA gene amplicons for all water control, DMSO control, and loperamide-treated samples. Ellipse lines show the 95 % confidence interval (standard deviation). Stress = 0.139 (n = 5 fish per condition). (B-D) NMDS plot calculated using Bray-Curtis beta-diversity (k=2) of percent normalized ASVs from 16S rRNA gene amplicons at each timepoint (B) T0 6 dpf (adonis2 PERMANOVA R2 = 0.43; p 0.05). The stress in indicated on each plot. (E) Beta-dispersion or within-condition dissimilarity index calculated using Bray-Curtis beta-diversity (n =15; 3 treatment groups for each of 5 samples per condition). **** p<0.001 for Loperamidetreatment, compared to DMSO. Wilcoxon test. Fig. S6. Growth parameters measured for zebrafish larvae. (A) Fish length, (B) rumpanus length, (C) tail width, and (D) eye diameter measurements of larval zebrafish at 6 dpf, 7 dpf, and 11 dpf (T0, T1, T5 after 24-hour treatment). All measurements are shown in millimeters (n = 10 fish per condition). * p